Doustną antykoagulację stosuje się w zapobieganiu incydentom zakrzepowo-zatorowym i
leczeniu żylnej choroby zakrzepowo-zatorowej (ŻChZZ) od lat 50. ubiegłego wieku. W …

Anticoagulant therapy is one of the most common forms of medical intervention. It is the
mainstay of prevention and treatment of thrombotic events. Omission of adequate …

Novel oral anticoagulants (NOACs) have become available for different clinical indications
such as the prevention of venous thromboembolism (VTE) after major orthopaedic surgery …

Background: Until recently, warfarin was the only oral anticoagulant. Due to its numerous
side effects, especially various types of bleeding, new oral anticoagulants with the same or …

The newer direct‐acting oral anticoagulants (DOACs)–apixaban, dabigatran, edoxaban,
rivaroxaban–offer many advantages over older anticoagulants such as warfarin. However, in …

Informasjon om de nye perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og
apiksaban. www. helsedirektoratet. no/publikasjoner/informasjon-om-de-nye-perorale …

Summary nOACs are an acceptable alternative to VKAs in certain situations–these are at
least as effective as warfarin for secondary prevention of VTE and for prevention of stroke …

With the advent of new oral anticoagulants a thorough assessment and evaluation of
benefits weighed against potential risks must be conducted. In a practical sense, what will …

Thromboembolic events are the leading cause of morbidity and mortality worldwide. From
the second half of the 20th century, vitamin K antagonists (VKAs), warfarin and …

Background Anticoagulation with vitamin K antagonists such as warfarin has historically
been used for the long term management of patients with thromboembolic disease …